Is Ind-Swift Labs. overvalued or undervalued?

As of 12 August 2025, the valuation grade for Ind-Swift Labs. has moved from attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued, with a PE ratio of 59.73, an EV to EBITDA of -5.91, and a PEG ratio of 0.00, which suggests that the stock may not be justified by its earnings growth potential.
In comparison to its peers, Ind-Swift Labs. has a much higher PE ratio than Sun Pharma (33.93) and Cipla (22.77), both of which are categorized as attractive. Additionally, the company's negative EV to EBITDA ratio raises concerns about its operational profitability relative to its enterprise value. While Ind-Swift Labs. has shown strong returns over the long term, its recent performance has lagged behind the Sensex, particularly over the past year, where it has declined by 39.74% compared to a modest 0.74% gain in the index.